Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic therapy for breast cancer

M J Kennedy1

  • 1Johns Hopkins Oncology Center, Baltimore, MD 21287, USA.

Current Opinion in Oncology
|November 25, 1997
PubMed
Summary
This summary is machine-generated.

Current breast cancer adjuvant therapy guidelines suggest 5 years for node-negative patients, but optimal duration remains debated. Combination chemotherapy with tamoxifen may improve survival in postmenopausal women.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The incidence of arthrogenic muscle inhibition in acute knee injuries: a prospective cohort study in a tertiary acute knee unit.

Asia-Pacific journal of sports medicine, arthroscopy, rehabilitation and technology·2025
Same author

Simultaneous "fix and replace" has non inferior survivorship compared to staged arthroplasty in acetabular fracture management at two year follow up.

Injury·2025
Same author

CTRIAL-IE (ICORG) 15-34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland.

Irish journal of medical science·2025
Same author

Heterogeneous integration of a III-V quantum dot laser on high thermal conductivity silicon carbide.

Optics letters·2023
Same author

Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.

Breast cancer research and treatment·2021
Same author

Low loss (Al)GaAs on an insulator waveguide platform.

Optics letters·2019

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Optimal adjuvant therapy duration for breast cancer patients with no involved axillary nodes is debated, with current recommendations suggesting 5 years.
  • Combination chemotherapy added to tamoxifen may improve disease-free survival in postmenopausal breast cancer patients.
  • Concerns exist regarding dose escalation of cyclophosphamide due to lack of benefit and increased risk of secondary leukemia.

Purpose of the Study:

  • To review current evidence on adjuvant therapy for breast cancer.
  • To discuss the efficacy and safety of various chemotherapy regimens.
  • To highlight emerging therapeutic agents for breast cancer management.

Main Methods:

  • Review of recently reported studies and clinical findings.

Related Experiment Videos

  • Analysis of data on adjuvant therapy duration and chemotherapy combinations.
  • Evaluation of novel agents including hormonal therapies and bisphosphonates.

    • Main Results:

    • No demonstrated benefit from cyclophosphamide dose escalation in adjuvant therapy; potential increased risk of secondary leukemia.
    • Combination chemotherapy with tamoxifen shows promise for improving disease-free survival in postmenopausal women.
    • Paclitaxel and doxorubicin combination shows high response rates but carries cardiotoxicity risks, potentially linked to pharmacokinetic interactions.

    Conclusions:

    • The optimal duration of adjuvant therapy for node-negative breast cancer remains an area of ongoing research and clinical debate.
    • Novel agents like aromatase inhibitors and bisphosphonates show potential utility in managing advanced or primary breast cancer.
    • Careful consideration of drug interactions and toxicity profiles is crucial when selecting chemotherapy regimens.